Letter to the EditorDrug-eluting balloons for peripheral artery disease: A meta-analysis of 7 randomized clinical trials and 643 patients
Section snippets
Acknowledgments
The authors of this manuscript have certified that they comply with the Principles of Ethical Publishing in the International Journal of Cardiology. Dr Biondi-Zoccai has consulted, lectured, and received career grant support from Medtronic.
References (9)
- et al.
Devices for infrainguinal endovascular therapy: menu à la carte or table d'hôte?
J Endovasc Ther
(2011) - et al.
Paclitaxel-coated versus uncoated balloon angioplasty reduces target lesion revascularization in patients with femoropopliteal arterial disease: a meta-analysis of randomized trials
Circ Cardiovasc Interv
(2012) - et al.
Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg
N Engl J Med
(2008) - et al.
Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial
Circulation
(2008)
Cited by (13)
Paclitaxel-coated balloons angioplasties for extra-long femoropopliteal artery atherosclerotic lesions (> 30 cm):12 months outcomes from a single center
2022, Journal of Interventional MedicineCitation Excerpt :Kaplan–Meier curves of primary patency and FF-CDTLR rates are shown in Figs. 1 and 2. Recent studies showed the superiority of PCBs as compared to standard angioplasty (plain old balloon angioplasty, POBA) in femoropopliteal ischemia.1–7 However, these studies were largely performed in relatively short lesions.
Drug-Coated Balloon Angioplasty in Clinical Practice for Below-the-Knee, Popliteal, and Crural Artery Lesions Causing Critical Limb Ischemia: 1-Year Results from the Spanish Luminor Registry
2020, Annals of Vascular SurgeryCitation Excerpt :Therefore, different clinical outcomes can be anticipated. Most clinical studies have demonstrated the anatomic benefits of DCBs over regular PTA balloons in terms of patency and clinically driven TLR reduction, mainly for the FP segment.3,4 Nevertheless, in patients with CLI, results of the first DCBs generation have not been clearly superior over those of PTA when clinical variables, such as amputation and mortality rates, are compared.12,13
Paclitaxel in endovascular devices: Identikit of a “serial killer”?
2019, EClinicalMedicinePaclitaxel-coated balloons and aneurysm formation in peripheral vessels
2015, Journal of Vascular SurgeryEffectiveness of drug-eluting balloons: Quantifying the information size from clinical trials
2013, International Journal of CardiologyDrug-coated Balloons in the Femoropopliteal Region: Dream or Reality?
2018, Vascular and Endovascular Review